Source comparison
MK-677 Dosage Guide: Research Application Comparison
The following table maps MK-677 dosage to primary research objectives, expected IGF-1 response, common adverse events, and professional assessment of suitability for multi-week protocols. 5–10mg daily GH pulsatility, sleep architecture, ghrelin signaling studi
This comparison does not assign a generated winner or score.
- The following table maps MK-677 dosage to primary research objectives, expected IGF-1 response, common adverse events, and professional assessment of suitability for multi-week protocols.
- 5–10mg daily
- GH pulsatility, sleep architecture, ghrelin signaling studies
- +40–60 ng/mL (20–30% from baseline)
- Minimal; transient appetite increase, rare mild edema
- Excellent for 12+ week studies
- Threshold dose for measurable effect; ideal for mechanistic research without confounding metabolic shifts
- 15–20mg daily
- Body composition observation, moderate anabolic endpoint trials
- +60–80 ng/mL (35–50% from baseline)
- Moderate appetite surge, mild fasting glucose elevation (+3–5 mg/dL), water retention in 20–30%
- Good for 8–12 week protocols with dietary control
- Sweet spot for balanced GH/IGF-1 elevation with manageable sides; requires appetite monitoring
- 25mg daily
- Clinical-standard anabolic research, lean mass trials, metabolic studies
- +80–100 ng/mL (50–70% from baseline)
- Significant appetite increase, transient insulin resistance (15–20% HOMA-IR rise), edema in 25–35%
- Moderate for 8 week cycles; longer requires glucose/insulin tracking
- Maximum dose for linear IGF-1 gains; metabolic monitoring essential beyond 8 weeks
- 30–50mg daily
- Aggressive GH restoration in deficiency models, geriatric frailty trials
- +100–120 ng/mL (60–80% from baseline; no further gains above 35mg)
- Carpal tunnel symptoms (12–18%), persistent edema, fasting glucose +6–10 mg/dL, possible joint stiffness
- Poor for healthy subjects; reserved for clinical deficiency contexts
- Diminishing returns; adverse event rate rises sharply without proportional IGF-1 benefit